Screener
Generate Biomedicines, Inc. GENB Current Debt
Current Debt at other companies
Other financials
Where this comes from
Reported directly by Generate Biomedicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityCurrent.
The source filing: Generate Biomedicines, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 6:01 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336437
| Line item | As of June 30, 2026 | As of December 31, 2025 |
|---|---|---|
| Accounts payable(1) | $5,653 | $3,837 |
| Accrued expenses and other current liabilities | 25,196 | 42,164 |
| Deferred revenue - current | 12,168 | 21,194 |
| Current portion of finance lease liabilities | 3,744 | 4,311 |
| Operating lease liabilities - current | 9,875 | 10,697 |
| Total current liabilities | 56,636 | 82,203 |
| Non-current liabilities: | ||
| Warrant to purchase convertible preferred stock | — | 1,205 |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Generate Biomedicines, Inc.'s current debt?
- Generate Biomedicines, Inc. (GENB) reported current debt of $3.74M in Q2 2026.
- What does current debt mean?
- The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.
Ask your AI about Generate Biomedicines, Inc.'s current debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude